US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by InflaRx N.V.

News headline image
InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026
From InflaRx N.V.
Via GlobeNewswire
Tickers IFRX
News headline image
InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development
From InflaRx N.V.
Via GlobeNewswire
Tickers IFRX
News headline image
InflaRx to Host Virtual Capital Markets Day
From InflaRx N.V.
Via GlobeNewswire
Tickers IFRX
News headline image
InflaRx Announces Participation in September Investor Conferences
From InflaRx N.V.
Via GlobeNewswire
Tickers IFRX
News headline image
InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones
From InflaRx N.V.
Via GlobeNewswire
Tickers IFRX
News headline image
InflaRx to Report Second Quarter 2026 Results on August 6, 2026
From InflaRx N.V.
Via GlobeNewswire
Tickers IFRX
News headline image
InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos
From InflaRx N.V.
Via GlobeNewswire
Tickers IFRX
News headline image
InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares
From InflaRx N.V.
Via GlobeNewswire
Tickers IFRX
News headline image
InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares
From InflaRx N.V.
Via GlobeNewswire
Tickers IFRX
News headline image
InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases
From InflaRx N.V.
Via GlobeNewswire
Tickers IFRX
News headline image
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
From InflaRx N.V.
Via GlobeNewswire
Tickers IFRX
News headline image
InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients
From InflaRx N.V.
Via GlobeNewswire
Tickers IFRX